MARKET

LFCR

LFCR

Lifecore Biomedical Inc
NASDAQ
6.21
+0.14
+2.31%
After Hours: 6.15 -0.06 -0.97% 16:17 07/26 EDT
OPEN
6.17
PREV CLOSE
6.07
HIGH
6.27
LOW
5.90
VOLUME
72.27K
TURNOVER
0
52 WEEK HIGH
11.46
52 WEEK LOW
4.470
MARKET CAP
191.67M
P/E (TTM)
-1.8686
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LFCR last week (0715-0719)?
Weekly Report · 4d ago
Laughing Water Capital Q2 2024 Letter
Seeking Alpha · 07/19 11:32
Lifecore Biomedical, Inc. (NASDAQ:LFCR) hedge funds owners may be pleased with recent gains after 46% loss over the past year
Hedge funds own 36% of Lifecore Biomedical, Inc. (NASDAQ:LFCR) The company is owned by institutions and the top 8% of the company's shares. Hedge funds own the most shares in the company, with a 36% stake. Most of the stock is held by hedge funds, but there is some institutional ownership in the business. We also see that insiders own shares in lifecore biomedical. You can see the history of insider ownership of the firm and its share price.
Simply Wall St · 07/17 13:21
Enzo Biochem: Is This Time Finally Different?
Enzo Biochem's stock is trading near historic lows. Stock has potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Company has $35m in cash after sale of Clinical Labs business to Labcorp Holdings. New CEO has been granted calls with a strike at $2 a share. Valuation potential of $2.00-3.22/share with $75-120m business value.
Seeking Alpha · 07/17 04:49
Weekly Report: what happened at LFCR last week (0708-0712)?
Weekly Report · 07/15 09:16
Lifecore Biomedical to Cut Nearly 9% of its Workforce, Book $1 Mln Costs
Dow Jones · 07/12 12:46
Lifecore Biomedical To Terminate 46 Full-Time Employees, About 9% Of Workforce; Estimates Termination Benefit Costs Of Approximately $1M
Benzinga · 07/12 12:08
LIFECORE BIOMEDICAL INC - ESTIMATES WILL INCUR TERMINATION BENEFIT COSTS OF ABOUT $1.0 MLN
Reuters · 07/12 12:04
More
About LFCR
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Webull offers Lifecore Biomedical Inc stock information, including NASDAQ: LFCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LFCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LFCR stock methods without spending real money on the virtual paper trading platform.